Results for RNA ( 623 )
Total RNA was prepared from cell line WM8. WM8 is a metastatic human melanoma cell line. This cell line features the specific N818K mutation in the c-KIT gene. This cell line expresses wild type BRAF, PTEN, N-RAS, and CDK4 genes. WM8 cells produce xenograft tumors when injected into immunocompromised mice.
Total RNA was prepared from cell line WM852. WM852 is a metastaic melanoma cell line with epithelial morphology. This cell line was established from the metastatic site (abdomen) in a 63-year -old male. This cell line contains a Q61R mutation at position 61 in the N-RAS gene. The Q61R is the most common NRAS mutation found in melanoma that is thought to occur due to UV and radiation exposure. This mutation leads to production of a constitutively active N-RAS protein that directs cells to grow and divide constantly. This cell line also expresses PTEN loss of function including hemizygous deletion. This cell line expresses wild type BRAF, c-KIT and CDK4 genes. WM852 cells produce xenograft tumors when injected into immunocompromised mice.
Total RNA was prepared from cell line WM852. WM852 is a metastaic melanoma cell line with epithelial morphology. This cell line was established from the metastatic site (abdomen) in a 63-year -old male. This cell line contains a Q61R mutation at position 61 in the N-RAS gene. The Q61R is the most common NRAS mutation found in melanoma that is thought to occur due to UV and radiation exposure. This mutation leads to production of a constitutively active N-RAS protein that directs cells to grow and divide constantly. This cell line also expresses PTEN loss of function including hemizygous deletion. This cell line expresses wild type BRAF, c-KIT and CDK4 genes. WM852 cells produce xenograft tumors when injected into immunocompromised mice.
Total RNA was prepared from cell line WM853-2. WM853-2 is a tumorigenic (VGP) primary melanoma cell line with competence for metastasis. This cell line was established from site on the back in a 71-year-old male. This cell line features the specific V600E (Val600Glu) mutation at codon 600 in the BRAF gene. This mutation causes constitutively active kinase activity and activation of MEK and ERK signaling pathway. This cell line expresses wild type PTEN, N-RAS, c-KIT, and CDK4 genes. WM853-2 cells produce xenograft tumors when injected into immunocompromised mice.
Total RNA was prepared from cell line WM853-2. WM853-2 is a tumorigenic (VGP) primary melanoma cell line with competence for metastasis. This cell line was established from site on the back in a 71-year-old male. This cell line features the specific V600E (Val600Glu) mutation at codon 600 in the BRAF gene. This mutation causes constitutively active kinase activity and activation of MEK and ERK signaling pathway. This cell line expresses wild type PTEN, N-RAS, c-KIT, and CDK4 genes. WM853-2 cells produce xenograft tumors when injected into immunocompromised mice.
Total RNA was prepared from cell line WM858. WM858 is a metastatic human melanoma cell line established from a metastatic site (right axillary nodes) in a 48-year-old female with level III malignant, superficial spreading melanoma. The subject displayed polypoid VGP with a tumor thickness of 3.24mm. This cell line features the specific V600E (Val600Glu) mutation at codon 600 in the BRAF gene. This mutation causes constitutively active kinase activity and activation of MEK and ERK signaling pathway. This cell line expresses wild type PTEN, N-RAS, c-KIT, and CDK4 genes. WM858 cells match with WM873-1 and WM873-2. These cells produce xenograft tumors when injected into immunocompromised mice.